Hyderabad: Bharat Biotech on Friday said it has committed to supply more than 500 million doses of covid-19 covaxin vaccine into the middle under immunization programs throughout the country.
Speaking at the virtual conference organized by the Indian Industrial Confederation, Suchitra Ella, Director of Implementing Director of City-Based Vaccine, said the company’s facilities in four cities – Hyderabad, Bengaluru, Pune and Ankaleshwar – currently produce covaxin.
“In short, if I have to tell you, this is a Covaxin trip from April 2020 to June 2021.
And it is still ongoing when we continue to produce, take commitment of more than 50 crores (500 million) doses to be submitted to the Indian government for the immunization program,” he said to tell trips Covaxin.
Minister of State for Health Bharati Pravin Pawar said in parliament on Tuesday that from January to July 16, 5.45 Crore (54.5 million) Covaxin doses by Bharat Biotech and 360 million) Crore Covishield doses have been supplied by the Indian Serum Institute to the Center , Suchitra Ella said the Phase 3 trial data was handed over to the drug controller General India because of its efficacy and the efficacy of vaccines against many variants of Coronavirus were also tested.
Covaxin shows the effectiveness of 77.8 percent on the protection of symptomatic Covid-19 and65.2plia against Delta B.6.617.2 variant, said Bharat Biotech recently, while announcing the final analysis of Jab.
It was said that the efficacy analysis showed Covaxin to 93.4 percent effective against the case of severe simptomatic Covid.
MD then said that when it came to vaccines not only for Covid-19, India, when compared to several other countries, having more capacity to produce large amounts of vaccines